Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06136221

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

Led by University of Pennsylvania · Updated on 2026-05-11

110

Participants Needed

2

Research Sites

160 weeks

Total Duration

On this page

Sponsors

U

University of Pennsylvania

Lead Sponsor

P

Pennsylvania Department of Health

Collaborating Sponsor

AI-Summary

What this Trial Is About

Remote healthcare monitoring for cirrhosis has shown promise in overcoming barriers to accessing specialty care, improving healthcare quality, and reducing mortality. The LiverWatch study is investigating whether a remote nutrition, physical activity, and education intervention can improve health outcomes in those with cirrhosis. In this clinical trial, individuals will be randomized to either enhanced usual care or the LiverWatch intervention. Both groups are given fitbits and asked to increase their step counts. Those in the Liverwatch group will be incentivized for increase their physical activity while also undergoing a personalized nutrition intervention and weekly symptom monitoring and cirrhosis education.

CONDITIONS

Official Title

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • English speaking
  • Aged 18 years or older
  • Home-dwelling
  • Diagnosis of cirrhosis with Child Turcotte-Pugh (CTP) B or C or a complication in the past 6 months such as hepatic encephalopathy, variceal bleeding, fluid overload, liver-related hospitalization, or symptom management with diuretics, non-absorbable disaccharides, rifaximin, or nonselective beta blockers
  • Patient and/or caregiver is able and willing to receive SMS text messages
  • Willing and able to wear personal fitness trackers and engage with study staff
Not Eligible

You will not qualify if you...

  • No access to a smartphone
  • Non-home dwelling
  • On hospice care
  • Model for end stage liver disease (MELD) score 5
  • Advanced hepatocellular carcinoma, BCLC C or higher
  • Hospitalization within the last 30 days
  • Deemed not appropriate by treating physician for medical reasons
  • Enrolled in other dietary or physical activity interventions
  • Receiving physical therapy as standard of care

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University of Michigan

Ann Arbor, Michigan, United States, 48109

Not Yet Recruiting

2

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

R

Richard Mason, PharmD

CONTACT

M

Marina Serper, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here